Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Qingxiu Zhong"'
Autor:
Xuejie Jiang, Ling Jiang, Jiaying Cheng, Fang Chen, Jinle Ni, Changxin Yin, Qiang Wang, Zhixiang Wang, Dan Fang, Zhengshan Yi, Guopan Yu, Qingxiu Zhong, Bing Z. Carter, Fanyi Meng
Publikováno v:
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-12 (2021)
Abstract Background Epigenetic dysregulation plays important roles in leukemogenesis and the progression of acute myeloid leukemia (AML). Histone acetyltransferases (HATs) and histone deacetylases (HDACs) reciprocally regulate the acetylation and dea
Externí odkaz:
https://doaj.org/article/e662629846894083a15f14a73bd9ccba
Autor:
Fanyi Meng, Dan Fang, Guopan Yu, Qingxiu Zhong, Jinle Ni, Bing Z. Carter, Zhixiang Wang, Ling Jiang, Jiaying Cheng, Fang Chen, Zhengshan Yi, Xuejie Jiang, Changxin Yin, Qiang Wang
Publikováno v:
Journal of Translational Medicine
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-12 (2021)
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-12 (2021)
Background Epigenetic dysregulation plays important roles in leukemogenesis and the progression of acute myeloid leukemia (AML). Histone acetyltransferases (HATs) and histone deacetylases (HDACs) reciprocally regulate the acetylation and deacetylatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c15a8a2ba252e7acd00630a9aa0f4307
https://doi.org/10.21203/rs.3.rs-89956/v1
https://doi.org/10.21203/rs.3.rs-89956/v1
Autor:
Qiuhua Zhu, Kaikai Huang, Changxin Yin, Xuejie Jiang, Bingjie Ding, Fang Chen, Zhixiang Wang, Qingxiu Zhong, Fanyi Meng, Yufeng Zhu, Xiaodong Li, Zhen Li
Publikováno v:
Oncotarget
Total body irradiation combined with chemotherapy is currently the most effective procedure as a preparative myeloablative regimen. However, resistance to radiotherapy and chemotherapy in refractory acute myeloid leukemia is associated with short-tim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::daaadf5b6b35d9611eac88e37a57fe8a
http://europepmc.org/articles/PMC5078070
http://europepmc.org/articles/PMC5078070
Autor:
Qiuhua Zhu, Xiaodong Li, Qingxiu Zhong, Xuejie Jiang, Changxin Yin, Fang Chen, Hongsheng Zhou, Ling Jiang, Chunli Wang, Lingxiu Zhang, Fanyi Meng, Guopan Yu, Bingjie Ding, Zhixiang Wang
Publikováno v:
Tumor Biology. 37:11409-11420
Accumulating evidence indicates that enhancer of zeste homolog 2 (EZH2) promotes the metastatic ability of solid tumors, but the role of EZH2 in extramedullary infiltration (EMI) in acute myeloid leukemia (AML) has not been thoroughly explored. In th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8683cb798b170fc6f9e86800b0e96c44
https://doi.org/10.1007/s13277-016-4983-4
https://doi.org/10.1007/s13277-016-4983-4
Autor:
Chunli Wang, Qingxiu Zhong, Yalei Zhang, Min Dai, Bingjie Ding, Qi Wei, Fanyi Meng, Xuejie Jiang, Ling Jiang, Zhixiang Wang, Xiaodong Li
Publikováno v:
Molecular and Clinical Oncology. 3:1139-1144
Decitabine (5-aza-2'-deoxycytidine; DAC) is a well-tolerated alternative to aggressive chemotherapy for leukemia, which induces differentiation and apoptosis of leukemic cells as a DNA hypomethylating agent. The aim of the present study was to invest
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4118773fb4edf26575e35e70c737aba6
https://doi.org/10.3892/mco.2015.605
https://doi.org/10.3892/mco.2015.605
Autor:
Bingjie, Ding, Zhixiang, Wang, Xuejie, Jiang, Xiaodong, Li, Chunli, Wang, Qingxiu, Zhong, Ling, Jiang, Min, Dai, Y U, Zhang, Q I, Wei, Fanyi, Meng
Publikováno v:
Molecular and clinical oncology. 3(5)
Decitabine (5-aza-2′-deoxycytidine; DAC) is a well-tolerated alternative to aggressive chemotherapy for leukemia, which induces differentiation and apoptosis of leukemic cells as a DNA hypomethylating agent. The aim of the present study was to inve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dea1c32b5e6fd4b65371847101a9514c
https://pubmed.ncbi.nlm.nih.gov/26623066
https://pubmed.ncbi.nlm.nih.gov/26623066
Autor:
Rui Cao, Zhixiang Wang, Lanlan Zhou, Zhongxin Zheng, Zhengshan Yi, Qingxiu Zhong, Libin Liao, Xiaodong Li, Bingjie Ding, Xuejie Jiang, Fanyi Meng, Changxin Yin
Publikováno v:
Disease Markers, Vol 2015 (2015)
Disease Markers
Disease Markers
Mixed phenotype acute leukemia (MPAL) is a complex entity expressing both lymphoid and myeloid immunophenotyping. In the present study, 47 MPAL, 60 lymphoid antigen-positive acute myeloid leukemia (Ly+AML), and 90 acute myeloid leukemia with common m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86a6ab25e6c43e96471bde9896e84f44
https://doaj.org/article/affc00da9cda4ce1800d76d7642c1033
https://doaj.org/article/affc00da9cda4ce1800d76d7642c1033
Autor:
Bing Z. Carter, Min Dai, Jieyu Ye, Yu Zhang, Guopan Yu, Qingxia Zhao, Shuang Liang, Fanyi Meng, Ling Jiang, Zhixiang Wang, Bingjie Ding, Xuejie Jiang, Qingxiu Zhong, Changxin Yin, Qifa Liu
Publikováno v:
Oncotarget
Introduction. Most acute myeloid leukemia (AML) patients with adverse prognosis either fail to achieve complete remission (CR) or relapse after short-term remission, new strategies are needed to improve therapeutic effect in these patients. Gene sile
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea00d37fed0a32cc77a4f93b0ba6f859
https://doi.org/10.1182/blood.v126.23.4932.4932
https://doi.org/10.1182/blood.v126.23.4932.4932
Decitabine Act As Demethylation Modulators in Acute Myeloid Leukemia for Reversal of Drug Resistance
Autor:
Qiuhua Zhu, Qingxiu Zhong, Xuejie Jiang, Changxin Yin, Bingjie Ding, Zhixiang Wang, Fanyi Meng, Kaikai Huang
Publikováno v:
Blood. 124:5218-5218
Background and objectives The DNA methyltransferase inhibitors decitabine represent archetypal drugs for epigenetic cancer therapy. One alternative approach for the treatment of (Acute Myelocytic Leukemia) AML is the use of hypomethylating agents, in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bcdb4be7e085b75746bb15c6045e3070
https://doi.org/10.1182/blood.v124.21.5218.5218
https://doi.org/10.1182/blood.v124.21.5218.5218
Publikováno v:
Blood. 124:5953-5953
Our previous study has been reported that AML1/ETO positive patients with highly expressed of APP were much easier to extramedullary infiltration, and got poor prognosis£¨followed-up median 35 ( 6-96 ) months, RFS in the high expression APP group w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c622aa5bfc256e2b8919698594a92f7c
https://doi.org/10.1182/blood.v124.21.5953.5953
https://doi.org/10.1182/blood.v124.21.5953.5953